PDF herunterladen
Digestive Disease Interventions 2020; 04(04): 389-394
DOI: 10.1055/s-0040-1721415
Review Article

Emerging Ablative and Transarterial Therapies for Pancreatic Cancer

Govindarajan Narayanan
1   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
3   Florida International University, Herbert Wertheim College of Medicine, Miami, Florida
,
Antonio Ucar
1   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Ripal T. Gandhi
1   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
3   Florida International University, Herbert Wertheim College of Medicine, Miami, Florida
,
Arian Nasiri
2   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
,
Prasuna Inampudi
1   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Nicole M. Wilson
3   Florida International University, Herbert Wertheim College of Medicine, Miami, Florida
,
Horacio Jose Asbun
1   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Pancreatic adenocarcinoma is a highly aggressive malignancy with a poor prognosis secondary to late presentation with metastases, challenging resection, and limited alternative therapies. Standard treatment strategies for pancreatic cancer include surgery, chemotherapy, and radiation therapy. These options can extend survival and/or relieve symptoms but are seldom curative. Thermal ablative therapies have been utilized in pancreatic cancer mostly in an open surgical setting. Irreversible electroporation (IRE) is a nonthermal ablative option for pancreatic cancer that uses high voltage, low energy direct current to induce cell death. IRE technology has been shown to spare critical structures such as blood vessels and bile ducts. The safety and efficacy of the percutaneous IRE in Stage 3 pancreas cancer has been studied and there is currently a Food and Drug Administration approved, randomized, controlled trial, and registry enrolling patients in the United States. Recent animal studies have also demonstrated that the advantages of IRE may extend beyond the local tumor effect. In addition to this local ablative option, a phase 3 trial is studying a transarterial option in the management of pancreatic cancer.

Keywords

pancreas - IRE - nanoknife


Publikationsverlauf

Eingereicht: 23. Juni 2020

Angenommen: 15. September 2020

Artikel online veröffentlicht:
19. November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Zhu H, Li T, Du Y, Li M. Pancreatic cancer: challenges and opportunities. BMC Med 2018; 16 (01) 214
    CrossrefPubMedGoogle Scholar
  • 2 Landman A, Feetham L, Stuckey D. Working together to reduce the burden of pancreatic cancer. Lancet Oncol 2020; 21 (03) 334-335
    CrossrefPubMedGoogle Scholar
  • 3 Orth M, Metzger P, Gerum S. et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019; 14 (01) 141
    CrossrefPubMedGoogle Scholar
  • 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (01) 7-30
    CrossrefPubMedGoogle Scholar
  • 5 Kleeff J, Korc M, Apte M. et al. Pancreatic cancer. Nat Rev Dis Primers 2016; 2: 16022
    CrossrefPubMedGoogle Scholar
  • 6 Tempero MA, Malafa MP, Chiorean EG. et al. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw 2019; 17 (03) 202-210
    Google Scholar
  • 7 Ferrone CR, Marchegiani G, Hong TS. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261 (01) 12-17
    CrossrefPubMedGoogle Scholar
  • 8 Ahn SS, Kim MJ, Choi JY, Hong HS, Chung YE, Lim JS. Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol 2009; 19 (10) 2448-2455
    CrossrefPubMedGoogle Scholar
  • 9 Amin Z, Theis B, Russell RC, House C, Novelli M, Lees WR. Diagnosing pancreatic cancer: the role of percutaneous biopsy and CT. Clin Radiol 2006; 61 (12) 996-1002
    CrossrefPubMedGoogle Scholar
  • 10 Palazzo L, Roseau G, Ruskone-Fourmestraux A. et al. Endoscopic ultrasonography in the local staging of primary gastric lymphoma. Endoscopy 1993; 25 (08) 502-508
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Sheridan MB, Ward J, Guthrie JA. et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 1999; 173 (03) 583-590
    CrossrefPubMedGoogle Scholar
  • 12 McNulty NJ, Francis IR, Platt JF, Cohan RH, Korobkin M, Gebremariam A. Multi--detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 2001; 220 (01) 97-102
    CrossrefPubMedGoogle Scholar
  • 13 George E, Wortman JR, Fulwadhva UP, Uyeda JW, Sodickson AD. Dual energy CT applications in pancreatic pathologies. Br J Radiol 2017; 90 (1080): 20170411
    CrossrefPubMedGoogle Scholar
  • 14 Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?. Eur J Cancer 2009; 45 (13) 2249-2252
    CrossrefPubMedGoogle Scholar
  • 15 Vroomen LGPH, Scheffer HJ, Melenhorst MCAM. et al. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol 2017; 27 (06) 2521-2531
    CrossrefPubMedGoogle Scholar
  • 16 Andriulli A, Festa V, Botteri E. et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19 (05) 1644-1662
    CrossrefPubMedGoogle Scholar
  • 17 Flak RV, Stender MT, Jensen TM. et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation—a Danish single center study of safety and feasibility. Scand J Gastroenterol 2019; 54 (02) 252-258
    CrossrefPubMedGoogle Scholar
  • 18 Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med 2019; 8 (11) E1945
    CrossrefPubMedGoogle Scholar
  • 19 Ruarus AH, Vroomen LGPH, Geboers B. et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 2020; 294 (01) 212-220
    CrossrefPubMedGoogle Scholar
  • 20 Rombouts SJ, Mungroop TH, Heilmann MN. et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study. J Cancer 2016; 7 (13) 1861-1866
    CrossrefPubMedGoogle Scholar
  • 21 Versteijne E, Suker M, Groothuis K. et al; Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 2020; 38 (16) 1763-1773
    CrossrefPubMedGoogle Scholar
  • 22 Shi S, Hua J, Yu XJ. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: randomized controlled trials are needed. J Surg Oncol 2019; 120 (07) 1284-1285
    CrossrefPubMedGoogle Scholar
  • 23 van Hilst J, de Rooij T, Klompmaker S. et al; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg 2019; 269 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 24 Yang DJ, Xiong JJ, Lu HM. et al. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci Rep 2019; 9 (01) 1159
    CrossrefPubMedGoogle Scholar
  • 25 Cunningham D, Chau I, Stocken DD. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27 (33) 5513-5518
    CrossrefPubMedGoogle Scholar
  • 26 Moris D, Machairas N, Tsilimigras DI. et al. Systematic review of surgical and percutaneous irreversible electroporation in the treatment of locally advanced pancreatic cancer. Ann Surg Oncol 2019; 26 (06) 1657-1668
    CrossrefPubMedGoogle Scholar
  • 27 Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20 (15) 3270-3275
    CrossrefPubMedGoogle Scholar
  • 28 Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and Marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87 (02) 161-167
    CrossrefPubMedGoogle Scholar
  • 29 Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33 (Suppl. 01) S18-S22
    CrossrefPubMedGoogle Scholar
  • 30 Hu J, Zhao G, Wang HX. et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011; 4: 11
    CrossrefPubMedGoogle Scholar
  • 31 Dhir M, Zenati MS, Hamad A. et al. FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol 2018; 25 (07) 1896-1903
    CrossrefPubMedGoogle Scholar
  • 32 Petrelli F, Coinu A, Borgonovo K. et al; Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD). FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 2015; 44 (04) 515-521
    CrossrefPubMedGoogle Scholar
  • 33 Conroy T, Desseigne F, Ychou M. et al; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
    CrossrefPubMedGoogle Scholar
  • 34 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18) 1691-1703
    CrossrefPubMedGoogle Scholar
  • 35 Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 2018; 8 (01) 8666
    CrossrefPubMedGoogle Scholar
  • 36 Fegrachi S, Besselink MG, van Santvoort HC, van Hillegersberg R, Molenaar IQ. Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford) 2014; 16 (02) 119-123
    CrossrefPubMedGoogle Scholar
  • 37 Pandya GJ, Shelat VG. Radiofrequency ablation of pancreatic ductal adenocarcinoma: the past, the present and the future. World J Gastrointest Oncol 2015; 7 (02) 6-11
    CrossrefPubMedGoogle Scholar
  • 38 Pezzilli R, Casadei R, Calculli L, Santini D, Morselli-Labate AM. NeoPan Study Group. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. Dig Liver Dis 2010; 42 (01) 73-74
    CrossrefPubMedGoogle Scholar
  • 39 D'Onofrio M, Barbi E, Girelli R. et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 2010; 16 (28) 3478-3483
    CrossrefPubMedGoogle Scholar
  • 40 Girelli R, Frigerio I, Giardino A. et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398 (01) 63-69
    CrossrefPubMedGoogle Scholar
  • 41 Cazzato RL, Garnon J, Ramamurthy N. et al. Percutaneous image-guided cryoablation: current applications and results in the oncologic field. Med Oncol 2016; 33 (12) 140
    CrossrefPubMedGoogle Scholar
  • 42 Niu L, Chen J, He L. et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas 2013; 42 (07) 1143-1149
    CrossrefPubMedGoogle Scholar
  • 43 Ahmed M, Brace CL, Lee Jr FT, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258 (02) 351-369
    CrossrefPubMedGoogle Scholar
  • 44 Lygidakis NJ, Sharma SK, Papastratis P. et al. Microwave ablation in locally advanced pancreatic carcinoma—a new look. Hepatogastroenterology 2007; 54 (77) 1305-1310
    PubMedGoogle Scholar
  • 45 Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007; 6 (04) 307-312
    CrossrefPubMedGoogle Scholar
  • 46 Narayanan G, Hosein PJ, Arora G. et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012; 23 (12) 1613-1621
    CrossrefPubMedGoogle Scholar
  • 47 Narayanan G, Hosein PJ, Beulaygue IC. et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 2017; 28 (03) 342-348
    CrossrefPubMedGoogle Scholar
  • 48 Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018; 9 (02) 275-281
    CrossrefPubMedGoogle Scholar
  • 49 Scheffer HJ, Vogel JA, van den Bos W. et al. The influence of a metal stent on the distribution of thermal energy during irreversible electroporation. PLoS One 2016; 11 (02) e0148457
    CrossrefPubMedGoogle Scholar
  • 50 Sugimoto K, Moriyasu F, Tsuchiya T. et al. Irreversible electroporation for nonthermal tumor ablation in patients with locally advanced pancreatic cancer: initial clinical experience in Japan. Intern Med 2018; 57 (22) 3225-3231
    CrossrefPubMedGoogle Scholar
  • 51 Rosemurgy AS, Ross SB, Vitulli PL, Malek R, Li J, Agah R. Safety study of targeted and localized intra-arterial delivery of gemcitabine in patients with locally advanced pancreatic adenocarcinoma. J Pancreat Cancer 2017; 3 (01) 58-65
    CrossrefPubMedGoogle Scholar
  • 52 Bonaventura P, Shekarian T, Alcazer V. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 2019; 10: 168-168
    CrossrefPubMedGoogle Scholar
  • 53 White SB, Zhang Z, Chen J, Gogineni VR, Larson AC. Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer. J Vasc Interv Radiol 2018; 29 (12) 1764-1769
    CrossrefPubMedGoogle Scholar
  • 54 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18 (16) 4266-4276
    CrossrefPubMedGoogle Scholar
  • 55 Zhao J, Wen X, Tian L. et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun 2019; 10 (01) 899
    CrossrefPubMedGoogle Scholar
  • 56 Scheffer HJ, Stam AGM, Geboers B. et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. OncoImmunology 2019; 8 (11) 1652532
    CrossrefPubMedGoogle Scholar